Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ornithine

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    iECURE Presents ECUR-506 OTC Deficiency Trial Data at ASGCT
    iECURE Presents ECUR-506 OTC Deficiency Trial Data at ASGCT

    13 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260513527972/en/iECURE-Presents-Preliminary-Clinical-Data-from-Ongoing-Clinical-Trial-of-ECUR-506-in-Ornithine-Transcarbamylase-Deficiency-at-the-ASGCT-Annual-Meeting

    BUSINESSWIRE
    13 May 2026
    Share Share
    iECURE to Present ECUR-506 Data in OTC Deficiency Trial
    iECURE to Present ECUR-506 Data in OTC Deficiency Trial

    28 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7232498

    FIRSTWORD PHARMA
    28 Apr 2026
    Share Share
    IECURE Earns FDA RMAT for ECUR-506 in Neonatal OTC Deficiency
    IECURE Earns FDA RMAT for ECUR-506 in Neonatal OTC Deficiency

    07 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260107943004/en/iECURE-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-ECUR-506-for-Neonatal-Onset-Ornithine-Transcarbamylase-OTC-Deficiency

    BUSINESSWIRE
    07 Jan 2026
    Share Share
    Orbus Therapeutics Presents Phase 3 STELLAR Trial Results
    Orbus Therapeutics Presents Phase 3 STELLAR Trial Results

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184342/36946/en/Orbus-Therapeutics-Announces-Oral-Presentation-of-Updated-Results-With-Blinded-Independent-Central-Review-from-the-Phase-3-STELLAR-Clinical-Trial-at-the-Society-for-Neuro-Oncology-.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    Arcturus Updates OTC Deficiency And Cystic Fibrosis Programs
    Arcturus Updates OTC Deficiency And Cystic Fibrosis Programs

    01 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240701483874/en

    BUSINESSWIRE
    01 Jul 2024
    Share Share
    iECURE Gets FDA Fast Track For OTC Deficiency Therapy
    iECURE Gets FDA Fast Track For OTC Deficiency Therapy

    07 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240507362839/en

    BUSINESSWIRE
    07 May 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.